OSCOTECInc.

039200KOSDAQPharmaceuticals

OSCOTECInc. (039200, KOSDAQ) reported KRW 100bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20214-28-294931Consolidated
20225-29-28144122Consolidated
20235-33-2813395Consolidated
202434-3-2171132Consolidated
20251005254230187Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2021-719.9%-732.6%63.7%-91.7%
2022-565.7%-548.6%84.8%-22.8%
2023-659.6%-575.4%71.4%-30.1%
2024-8%-4.7%77.5%-1.2%
202552.2%54.5%81.3%29.1%

Revenue moved 2,458.2% between 2021 and 2025.

Net profit was positive in the 1 most recent year on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 1,331bn
Close priceKRW 34,800
Listed shares38,258,176
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Lee Sang-hyeon (이상현)Representative Director (CEO)Inside director26 years
Yoon Tae-yeong (윤태영)Representative Director (CEO)Inside director6 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)57
Women25 (43.9%)
Average tenure6 years
Annual pay, menKRW 66,000,000
Annual pay, womenKRW 56,000,000
Pay ratio, women to men84.8%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →